Horm Metab Res
DOI: 10.1055/a-2295-9335
Original Article: Endocrine Care

Clinical Efficacy of Bisphosphonates in Treating Osteoporosis in Diabetes Patients: A Meta-Analysis

Yuan-Xun Yang
1   Orthopedics, The First People’s Hospital of Jinan, Jinan, China
,
Yan Jin
2   AIDS Prevention and Control Institute, Jinan Center for Disease Control and Prevention, Jinan, China
› Institutsangaben

Abstract

The aim of the study was to explore the clinical efficacy of bisphosphonates in patients with osteoporosis in diabetes patients by meta-analysis. Six databases were systematically searched from inception to January 30,2023. Studies evaluating the treatment of diabetic osteoporosis with bisphosphonates were included. Key outcome measures, such as bone mineral density (BMD), bone metabolism markers, pain improvement, and safety assessments, were extracted and analyzed. STATA MP V17.0 was used to calculate the combined effect size. After searching Chinese and English databases, 15 studies met the inclusion criteria of this study. The results of the meta-analysis showed that the BMD of patients with osteoporosis in diabetes increased significantly after bisphosphonate treatment, and the lumbar BMD increased by 0.08 g/cm² (95% CI: 0.05–0.11). Femoral neck BMD increased by 0.06 g/cm² (95% CI: 0.01–0.11); Ward’s triangle BMD increased 0.07 g/cm² (95% CI: 0.04–0.09); and trochanter BMD increased by 0.06 g/cm² (95% CI: 0.04–0.08). In addition, bone alkaline phosphatase increased 1.95 μg/l (95% CI: 1.18–2.72), while serum tartrate-resistant acid phosphatase-5b decreased 1.28 U/l (95% CI: –1.81–0.75). Moreover, improvements in pain were statistically significant. The effects of bisphosphonates on osteocalcin (MD: –0.07; 95% CI: –1.12–1.25), serum calcium (MD: 0.01; 95% CI: –0.03–0.04), serum phosphorus (MD: 0.04; 95% CI: –0.03–0.10) and medication safety (OR: 1.75; 95% CI: 1.29–2.37) were not statistically significant. Bisphosphonates have a significant positive effect on bone mineral density and bone metabolism in patients with osteoporosis in diabetes and have good safety.



Publikationsverlauf

Eingereicht: 05. Dezember 2023

Angenommen nach Revision: 24. März 2024

Artikel online veröffentlicht:
26. April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023; 402: 203-234
  • 2 Mazurenko E, Malyutina S, Shcherbakova L. et al. World congress on osteoporosis, osteoarthritis and musculoskeletal diseases (WCO-IOF-ESCEO 2022). Aging Clin Exp Res 2022; 34: 35-474
  • 3 Dimai HP, Fahrleitner-Pammer A. Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol 2022; 36: 101780
  • 4 Wu B, Fu Z, Wang X. et al. A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment. Front Endocrinol (Lausanne) 2022; 13: 1052592
  • 5 Hofbauer LC, Busse B, Eastell R. et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2022; 10: 207-220
  • 6 Ebeling PR, Nguyen HH, Aleksova J. et al. Secondary osteoporosis. Endocr Rev 2022; 43: 240-313
  • 7 Wang P, Zhang Y, Shan R. et al. Association between trajectories of fasting plasma glucose and risk of osteoporosis in non-diabetic and diabetic populations. Front Public Health 2022; 10: 960928
  • 8 LeBoff MS, Greenspan SL, Insogna KL. et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33: 2049-2102
  • 9 Song S, Guo Y, Yang Y. et al. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther 2022; 237: 108168
  • 10 Fuggle N, Al-Daghri N, Bock O. et al. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res 2022; 34: 2625-2634
  • 11 McConnell M, Shieh A. Polypharmacy in osteoporosis treatment. Clin Geriatr Med 2022; 38: 715-726
  • 12 Wang M, Wu YF, Girgis CM. Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. JBMR Plus 2022; 6: e10629
  • 13 Chen PW, Su HY, Tu YK. et al. Association of bisphosphonates with diabetes risk and glycemic control: a meta-analysis. Osteoporos Int 2023; 34: 387-397
  • 14 Xiong Z, Yi P, Tang X. et al. Meta-analysis of the efficacy and safety of alendronate combined with atorvastatin in the treatment of osteoporosis in diabetes mellitus. Biomed Res Int 2022; DOI: 10.1155/2022/6747469.
  • 15 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
  • 16 Tong J, Chen Z, Sun G. et al. The efficacy of pulsed electromagnetic fields on pain, stiffness, and physical function in osteoarthritis: a systematic review and meta-analysis. Pain Res Manag 2022; DOI: 10.1155/2022/9939891.
  • 17 Huang Q, Lin J, Han R. et al. Using virtual reality exposure therapy in pain management: a systematic review and meta-analysis of randomized controlled trials. Value Health 2022; 25: 288-301
  • 18 Dai C, Liang G, Zhang Y. et al. Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures, especially in Eastern Asia: a systematic review and meta-analysis. J Orthop Surg Res 2022; 17: 161
  • 19 Hesari E, Sanjari M, Mansourzadeh MJ. et al. Osteoporosis medication adherence tools: a systematic review. Osteoporos Int 2023; 34: 1535-1548
  • 20 Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 2007; 24: 1314-1320
  • 21 Iwamoto J, Sato Y, Uzawa M. et al. Retracted: three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res Clin Pract 2011; 93: 166-173
  • 22 Deng LL, Chen HL, Li MS. Therapeutic effect of alendronate plus caltrate or caltrate alone in type 2 diabetic elderly women with osteoporosis. Chin J Osteopor 2010; 16: 132-135
  • 23 Wang YL, Wang HB, Yang F. et al. The effect of alendronate on bone biochemical indicator of Type 2 DM postmenopausal women with lower BMD. J Clin Intern Med 2006; 23: 595-597
  • 24 Wang HY, Cai XY, Ge J. et al. Effect of Risedronate on type 2 diabetes mellitus complicated with postmenopausal osteoporosis. Shanghai Med J 2006; 29: 429-431
  • 25 Maugeri D, Panebianco P, Rosso D. et al. Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis. Arch Gerontol Geriatr 2002; 34: 117-122
  • 26 Keegan TH, Schwartz AV, Bauer DC. et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004; 27: 1547-1553
  • 27 Han RY, Wu ZZ, Liu SJ. et al. Efficacy of zoledronic acid plus caltrate don in the treatment of diabetic osteoporosis. Prog Mod Biomed 2015; 15: 104-106
  • 28 Ren H, Zhang ZL, Cai W. et al. Efficacy of zoledronic acid combined with calcium carbonate D3 in the treatment of diabetic osteoporosis and its effects on bone mineral density and bone metabolism indexes. Hebei Med 2020; 26: 45-50
  • 29 Hu Q, Wang Q, Liu F. et al. Combination of calcitriol and zoledronic acid on PINP and β-CTX in postoperative patients with diabetic osteoporosis: a randomized controlled trial. Dis Markers 2022; DOI: 10.1155/2022/6053410.
  • 30 Guo YJ, Wu J. Effect of alendronate combined with insulin on the treatment of diabetic osteoporosis. J Clin Med Pract 2019; 23: 69-72
  • 31 Ye CC, Jiang H, Pan LQ. Alendronate sodium combined with insulin for osteoporosis in patients with type 2 diabetes mellitus. Chin J Gen Pract 2017; 15: 1714-1717
  • 32 Chen H. Observation on effect of alendronate combined with calcarea carbonica D_3 tablet in the treatment of type 2 diabetic osteoporosis. Chin J Pharmacoepidemiol 2015; 24: 451-453 + 459
  • 33 Li WQ, Shi CH. Effects of alendronate sodium combined with calcium carbonate D3 tablets on bone mineral density and bone metabolism indexes in patients with diabetic osteoporosis. J Guangxi Med Univ 2016; 33: 831-833
  • 34 Wang F, Ren HQ, Shen XB. Effect of insulin combined alendronate sodium on bone mineral density and levels of serum BAP TRAP-5b and BGP in aged patients with type 2 diabetes mellitus with osteoporosis. J Hainan Med Univ 2016; 22: 1387-1389+1393
  • 35 Sheu A, Greenfield JR, White CP. et al. Assessment and treatment of osteoporosis and fractures in type 2 diabetes. Trends Endocrinol Metab 2022; 33: 333-344
  • 36 Schwartz AV, Backlund JC, de Boer IH. et al. Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes Endocrinol 2022; 10: 509-518
  • 37 Duhan N, Siwach RC, Yadav K. et al. Expression of concern: comparative evaluation of isosorbide mononitrate and alendronate in management of postmenopausal osteoporosis. Arch Gynecol Obstet 2023; 308: 1655
  • 38 Everts-Graber J, Bonel H, Lehmann D. et al. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporos Int 2023; 34: 1961-1973
  • 39 Zhou Q, Guan Z, Liu S. et al. The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice. Aging (Albany NY) 2022; 14: 272-285
  • 40 Balaji A, Boratne AV, Mishra A. Reducing risk of type 2 diabetes mellitus with alendronate - a promising possibility for the Indian population. Indian J Pharmacol 2022; 54: 65-66
  • 41 Viggers R, Al-Mashhadi Z, Starup-Linde J. et al. Alendronate use and risk of type 2 diabetes: a nationwide Danish nested case-control study. Front Endocrinol (Lausanne) 2021; 12: 771426